Flyer

Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease

4th EuroSciCon Conference on Neurology & Neurological Disorders
July 12 -13, 2018 Paris , France

Yung-Feng Liao, Bo-Jeng Wang, Yun-Wen Chen and Pei-Yi Wu

Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan

Scientific Tracks Abstracts: J Neurol Neurosci

Abstract:

Proteolytic processing of amyloid precursor protein (APP) C-terminal fragments (CTFs) by γ-secretase underlies the pathogenesis of Alzheimer’s disease (AD). An RNA interference screen using APP-CTF [99-residue CTF (C99)] and Notch-specific γ-secretase interaction assays identified a unique ErbB2-centered signaling network that was predicted to preferentially govern the proteostasis of APP-C99. We then found that ErbB2 effectively suppressed autophagic flux by physically dissociating Beclin-1 from the Vps34–Vps15 complex independent of its kinase activity. Down-regulation of ErbB2 by CL-387,785 decreased the levels of C99 and secreted amyloid-β in cellular, zebra fish and mouse models of AD, through the activation of autophagy. Oral administration of an ErbB2-targeted CL-387,785 for 3 weeks significantly improves the cognitive functions of APP/PS1 transgenic mice. This work unveils a non-canonical function of ErbB2 in modulating autophagy and establishes ErbB2 as a novel therapeutic target for AD.

Biography :

Yung-Feng Liao has completed his PhD in Biochemistry and Molecular Biology from University of Georgia (Athens, Georgia, USA) and Post-doctoral studies from Harvard Medical School/ Massachusetts General Hospital/Brigham and Women’s Hospital (Boston, Massachusetts, USA). He is the Principal Investigator of the Laboratory of Molecular Neurobiology in the Institute of Cellular and Organismic Biology, Academia Sinica, a premier research institution in Taiwan. He has published more than 50 papers in reputed journals and has been serving either as an Editorial Board Member or as a Peer Reviewer of prestigious journals.

E-mail: yliao@sinica.edu.tw